-
Thousands join Danish war vets' silent march after Trump 'insult'
-
Gaza civil defence says Israeli strikes kill 28
-
Pakistan spin out Australia in second T20I to take series
-
Melbourne champion Rybakina never doubted return to Wimbledon form
-
Luis Enrique welcomes Ligue 1 challenge from Lens
-
Long truck lines at Colombia-Ecuador border as tariffs loom
-
Ex-prince Andrew dogged again by Epstein scandal
-
Separatist attacks in Pakistan kill 21, dozens of militants dead
-
'Malfunction' cuts power in Ukraine. Here's what we know
-
Arbeloa backs five Real Madrid stars he 'always' wants playing
-
Sabalenka 'really upset' at blowing chances in Melbourne final loss
-
Britain, Japan agree to deepen defence and security cooperation
-
Rybakina keeps her cool to beat Sabalenka in tense Melbourne final
-
France tightens infant formula rules after toxin scare
-
Blanc wins final women's race before Winter Olympics
-
Elena Rybakina: Kazakhstan's Moscow-born Melbourne champion
-
Ice-cool Rybakina beats Sabalenka in tense Australian Open final
-
Pakistan attacks kill 15, dozens of militants dead: official
-
Ten security officials, 37 militants killed in SW Pakistan attacks: official
-
Epstein survivors say abusers 'remain hidden' after latest files release
-
'Full respect' for Djokovic but Nadal tips Alcaraz for Melbourne title
-
Wollaston goes back-to-back in the Cadel Evans road race
-
Women in ties return as feminism faces pushback
-
Ship ahoy! Prague's homeless find safe haven on river boat
-
Britain's Starmer ends China trip aimed at reset despite Trump warning
-
Carlos Alcaraz: rare tennis talent with shades of Federer
-
Novak Djokovic: divisive tennis great on brink of history
-
History beckons for Djokovic and Alcaraz in Australian Open final
-
Harrison, Skupski win Australian Open men's doubles title
-
Epstein offered ex-prince Andrew meeting with Russian woman: files
-
Jokic scores 31 to propel Nuggets over Clippers in injury return
-
Montreal studio rises from dark basement office to 'Stranger Things'
-
US government shuts down but quick resolution expected
-
Mertens and Zhang win Australian Open women's doubles title
-
Venezuelan interim president announces mass amnesty push
-
China factory activity loses steam in January
-
Melania Trump's atypical, divisive doc opens in theatres
-
Bad Bunny set for historic one-two punch at Grammys, Super Bowl
-
Five things to watch for on Grammys night Sunday
-
Venezuelan interim president proposes mass amnesty law
-
Rose stretches lead at Torrey Pines as Koepka makes cut
-
Online foes Trump, Petro set for White House face-to-face
-
Seattle Seahawks deny plans for post-Super Bowl sale
-
US Senate passes deal expected to shorten shutdown
-
'Misrepresent reality': AI-altered shooting image surfaces in US Senate
-
Thousands rally in Minneapolis as immigration anger boils
-
US judge blocks death penalty for alleged health CEO killer Mangione
-
Lens win to reclaim top spot in Ligue 1 from PSG
-
Gold, silver prices tumble as investors soothed by Trump Fed pick
-
Ko, Woad share lead at LPGA season opener
Appetite-regulating hormones in focus as first Nobel Prizes fall
Research into hormones that regulate appetite is seen leading the race for the Nobel Prize in Medicine, to be awarded Monday -- the first in this year's Nobel season.
At a time when more than one billion people suffer from obesity, research into the hormone called "glucagon-like peptide 1" (GLP-1) could be given the nod for the Nobel Prize in Physiology or Medicine this year, experts said.
A new generation of drugs using GLP-1 agonists -- including blockbuster brands Ozempic, Wegovy and Mounjaro -- has provided a valuable tool to fight obesity and diabetes globally.
"Many are guessing that it (the Nobel Prize in Medicine) will go to the people behind GLP-1," Lars Brostrom, science editor at public broadcaster Sveriges Radio, told AFP.
That could help researchers from major US institutions once again dominate the Nobel Prizes in sciences, which are to be announced this week in Stockholm.
But, even if that happens, US politics is to cast a shadow over them, given budget cuts to science programmes ordered by President Donald Trump's government.
Since January, the US National Institutes of Health (NIH) has terminated 2,100 research grants totalling around $9.5 billion and $2.6 billion in contracts, according to an independent database called Grant Watch.
Such cuts could fuel debate over the growing risk that the United States could lose its edge in scientific research.
"In the post-war period, the US has taken over Germany's role as the world's leading scientific nation," Hans Ellegren, secretary general of the Royal Swedish Academy of Sciences, which awards Nobel Prizes in physics, chemistry, and economics, told AFP.
"When they now start cutting research funding, it threatens the country's position."
- Many contenders -
When it comes to GLP-1, as with many other discoveries, it can be hard to narrow down who exactly deserves to be honoured when many scientists around the world have made significant contributions.
Brostrom said some names often speculated upon are Danish physician Jens Juul Holst, and Joel Habener, a professor of medicine at Harvard, as well as Canadian endocrinologist Daniel Drucker and Yugoslav-born American chemist Svetlana Mojsov.
Despite treatments such as Ozempic being recently introduced, and the Nobel Assembly at the Karolinska Institute more often honouring discoveries that are decades old, "it could also be perfect timing" for GLP-1 recognition "because the discovery itself was made back in the 80s", Brostrom said.
In the same field, research on ghrelin, a hormone that stimulates appetite, could earn a Nobel Prize for two Japanese researchers, Kenji Kangawa and Masayasu Kojima, according to David Pendlebury, who heads research analysis at the firm Clarivate -- which predicts potential Nobel winners based on the number of citations of their work.
Pendlebury said that would also form "a nice bookend to a 1994 discovery" by geneticist Jeffrey Friedman, who discovered another appetite-regulating hormone, leptin, and who has previously been spotlighted by Clarivate.
"We have a combination of very nice discoveries, a hormone for appetite, a hormone that suppresses appetite, and this may also play into a lot of speculation of a prize for the GLP-1," he told AFP.
Clarivate also said the work of German medical professor Andrea Ablasser, American virologist Glen N. Barber, and Chinese-American biochemist Zhijian "James" Chen could be honoured "for elucidating the cGAS-STING pathway, a fundamental mechanism of innate immunity".
It noted that Canadian biologist John E. Dick could also be a contender "for identifying leukaemia stem cells and establishing their relevance in therapy failure".
- 'Invisibility cloak' -
For the Nobel Prize in Physics on Tuesday, experts at Sweden's public radio cited research into metamaterials, which has been buzzed about for several years.
British physicist John B. Pendry has in particular been frequently mentioned for his "invisibility cloak" -- a theoretical method to redirect electromagnetic fields around an object.
The Nobel season continues Wednesday with the prize for chemistry, followed on Thursday by the closely watched literature prize and on Friday the peace prize, which Donald Trump has argued should go to him.
The economics prize wraps up the Nobel season on October 13.
In addition to each honour, the prize includes a diploma, a gold medal, and a check for 11 million Swedish kronor ($1.2 million).
T.Bondarenko--BTB